DK2507635T3 - Biokemisk serum-biomarkør - Google Patents

Biokemisk serum-biomarkør Download PDF

Info

Publication number
DK2507635T3
DK2507635T3 DK10805698.7T DK10805698T DK2507635T3 DK 2507635 T3 DK2507635 T3 DK 2507635T3 DK 10805698 T DK10805698 T DK 10805698T DK 2507635 T3 DK2507635 T3 DK 2507635T3
Authority
DK
Denmark
Prior art keywords
bag3
protein
antibodies
soluble
heart disease
Prior art date
Application number
DK10805698.7T
Other languages
English (en)
Inventor
Maria Caterina Turco
Original Assignee
Biouniversa Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa Srl filed Critical Biouniversa Srl
Application granted granted Critical
Publication of DK2507635T3 publication Critical patent/DK2507635T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (13)

1. Fremgangsmåde til detektering af tilstedeværelsen og/eller koncentration af det opløselige BAG3-protein i en ukendt biologisk prøve, omfattende trinnene at: a. bestemme tilstedeværelses- eller koncentrationsværdier af opløselig BAG3 i en tidligere opnået biologisk prøve, bestående af serum eller plasma; b. sammenligne de opnåede værdier fra prøven med referenceværdier eller med værdierne opnået fra de biologiske referenceprøver, c. eventuelt, bestemme yderligere grupperinger af lignende værdier eller inddeling i grupper med statistisk forskellige gennemsnitsværdier, d. associere tilstedeværelsen og/eller niveauet af opløselig BAG3 med en patologisk tilstand valgt fra gruppen bestående af hjertesygdom eller bugspytkirtelcancer.
2. Fremgangsmåde ifølge krav 1, hvor bestemmelsestrin b) udføres med specifikke ligander for opløselig BAG3.
3. Fremgangsmåde ifølge et hvilket som helst af kravene 1 eller 2, hvor den biologiske prøve er af human oprindelse.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1-3, hvor antikoagulerende stoffer er tilsat til den biologiske prøve.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 2-4, hvor de specifikke ligander er antistoffer.
6. Fremgangsmåde ifølge krav 5, hvor bestemmelsestrin b) udføres ved hjælp af monoklonale, polyklonale eller rekombinante anti-BAG3-antistoffer eller deres fragmenter (.scFv; diabodies, minibodies).
7. Fremgangsmåde ifølge krav 6 hvor antistoffet er monoklonalt og genkender mindst én BAG3-epitop valgt fra gruppen bestående af de følgende aminosyresekvenser: 18-33, 385-399 eller 533-547 fra primærsekvensen af BAG3 eller er et rekombinant derivat deraf, humaniseret eller på anden vis modificeret ved rekombination.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 2-7, hvor antistofferne eller liganderne er mærket med fluorophorer, chromophorer eller enzymer der er i stand til at omdanne et substrat til en chromophor.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 2-8, hvor bestemmelsestrin b) udføres under anvendelse af sandwich ELISA med en BAG3 indfangningsligand og en detektionsligand, hvor både den første og den anden er monoklonale antistoffer og hvor det andet antistof genkender en epitop forskellig fra en genkendt af det anvendte immobiliserede antistof, eller er en blanding af flere monoklonale antistoffer.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 5-9, hvor den patologiske tilstand er hjertesygdom.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1-10, hvor hjertesygdommen (trin (e)) er valgt fra gruppen bestående af: angina pectoris, præinfarkt-angina, myokardieinfarkt, hjerteinsufficiens, akut koronarsygdom, akut hjerteinsufficiens, kronisk hjerteinsufficiens eller iatrogen hjertesygdom.
12. Anvendelse af det humant opløselige BAG3-protein som en serummarkør af en patologisk tilstand valgt fra hjertesygdom eller en bugspytkirtelcancer.
13. Anvendelse ifølge krav 12, hvor hjertesygdommen er valgt fra gruppen bestående af: angina pectoris, præinfarkt-angina, myokardieinfarkt, hjerteinsufficiens, akut koronarsygdom, akut hjerteinsufficiens, kronisk hjerteinsufficiens og iatrogen hjertesygdom.
DK10805698.7T 2009-12-04 2010-12-03 Biokemisk serum-biomarkør DK2507635T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A002154A IT1397083B1 (it) 2009-12-04 2009-12-04 Marcatore biochimico serico
PCT/EP2010/068836 WO2011067377A1 (en) 2009-12-04 2010-12-03 Biochemical serum marker

Publications (1)

Publication Number Publication Date
DK2507635T3 true DK2507635T3 (da) 2015-02-09

Family

ID=42244209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10805698.7T DK2507635T3 (da) 2009-12-04 2010-12-03 Biokemisk serum-biomarkør

Country Status (14)

Country Link
US (1) US8673585B2 (da)
EP (1) EP2507635B1 (da)
JP (1) JP5677450B2 (da)
KR (1) KR101851392B1 (da)
CN (1) CN102725638B (da)
AU (1) AU2010326600B2 (da)
BR (1) BR112012013418B1 (da)
CA (1) CA2782544C (da)
DK (1) DK2507635T3 (da)
ES (1) ES2530734T3 (da)
HK (1) HK1176678A1 (da)
IT (1) IT1397083B1 (da)
PT (1) PT2507635E (da)
WO (1) WO2011067377A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1397083B1 (it) 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
KR101436684B1 (ko) 2012-03-09 2014-09-01 가톨릭대학교 산학협력단 저산소성 허혈 예방 또는 치료용 조성물
ITMI20130403A1 (it) * 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico
EP2676966A1 (en) 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 as biochemical serum and tissue marker
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
ITUB20155097A1 (it) 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
IT201600069391A1 (it) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare
IT201600111877A1 (it) 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
JP6873460B2 (ja) * 2017-01-12 2021-05-19 テオリアサイエンス株式会社 被検者が膵臓癌に罹患している可能性を試験する方法
IT201700113648A1 (it) * 2017-10-10 2019-04-10 Biouniversa Srl Anti-BAG3 antibodies as therapeutic reagent in cardiovascular diseases
US20210024623A1 (en) 2017-07-28 2021-01-28 Intrepida Bio, Inc. Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease
WO2019178489A1 (en) * 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200618A2 (en) * 1999-07-09 2002-05-02 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
JP2005229874A (ja) * 2004-02-18 2005-09-02 Institute Of Physical & Chemical Research Ｂａｇ３ドメインポリペプチド及びその用途
CA2650507A1 (en) * 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
CN101505791A (zh) * 2006-08-14 2009-08-12 株式会社未来创药研究所 使用抗桥粒芯蛋白3抗体的癌症的诊断和治疗
RU2537245C2 (ru) * 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
CN101358976A (zh) * 2008-04-28 2009-02-04 北京华大吉比爱生物技术有限公司 检测六项肿瘤标志物的微阵列-酶联免疫检测试剂盒
IT1397083B1 (it) 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico

Also Published As

Publication number Publication date
KR20120121391A (ko) 2012-11-05
BR112012013418A2 (pt) 2017-12-12
CA2782544A1 (en) 2011-06-09
PT2507635E (pt) 2015-02-24
CA2782544C (en) 2019-08-06
KR101851392B1 (ko) 2018-04-23
JP5677450B2 (ja) 2015-02-25
EP2507635B1 (en) 2014-11-19
ITMI20092154A1 (it) 2011-06-05
CN102725638A (zh) 2012-10-10
BR112012013418B1 (pt) 2019-11-26
IT1397083B1 (it) 2012-12-28
JP2013513101A (ja) 2013-04-18
AU2010326600B2 (en) 2016-04-28
ES2530734T3 (es) 2015-03-05
WO2011067377A1 (en) 2011-06-09
HK1176678A1 (en) 2013-08-02
CN102725638B (zh) 2014-08-20
EP2507635A1 (en) 2012-10-10
US20120244561A1 (en) 2012-09-27
US8673585B2 (en) 2014-03-18
AU2010326600A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
DK2507635T3 (da) Biokemisk serum-biomarkør
Chen et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia
Megliorino et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection
Lian et al. CACYBP enhances cytoplasmic retention of P27Kip1 to promote hepatocellular carcinoma progression in the absence of RNF41 mediated degradation
US11913956B2 (en) Tumor blood marker, use thereof, and kit comprising the same
EP2452948B1 (en) New tumor marker
Lukic et al. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis
JP2024038346A (ja) 血液から癌を診断する方法
Matsumoto et al. Anti-HuC and-HuD autoantibodies are differential sero-diagnostic markers for small cell carcinoma from large cell neuroendocrine carcinoma of the lung
US20140363832A1 (en) Molecular marker for the early detection of malignant pleural mesothelioma and the methods of its expression analysis using blood and pleural effusion samples
Mou et al. Immunoproteomics to identify tumor-associated antigens eliciting humoral response
WO2016143805A1 (ja) 膀胱がんの検出方法
US8975030B2 (en) Method for cancer detection
JP2019045486A (ja) 癌を検出する方法及び検出試薬
WO2013039166A1 (ja) 抗ｗｔ１抗体の測定方法
Xu et al. Identification of FRAS1 as a human endometrial carcinoma-derived protein in serum of xenograft model
US20240264161A1 (en) Biomarkers and uses thereof
WO2022075113A1 (ja) 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー
AU2014203702B2 (en) New tumor marker
Chen et al. Research Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia
Dumonceau et al. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis☆